The Acute Myeloid Leukemia Channel is supported through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Circulating tumor DNA enables sensitive and universally applicable MRD monitoring in AML
Tian Yi Zhang, MD, PhD, Stanford Cancer Institute, Stanford , CA, presents data on the use of circulating tumor DNA (ctDNA) for measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML), which allows for personalized and bespoke monitoring of the disease. Dr Zhang discusses this in the context of the updated European LeukemiaNet (ELN) guidelines for MRD, and highlights the potential of ctDNA-MRD to predict relapse-free survival and overall survival. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
